English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tag: Lung Cancer
Ochsner Medical Center – Baton Rouge performs robotic-assisted lung biopsy
Ochsner Medical Center – Baton Rouge now offers robotic-assisted bronchoscopy using the Ion robotic platform, a new, minimally invasive option for lung biopsy.
Study supports precision radiation therapy in lung cancer
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC).
DITCHING THE VAPE MAY BE BEST WAY TO BREATHE EASY this “Love Your Lungs” Week
As many as 70% of smokers looking to quit say they enlist the help of e-cigarettes or vaping devices to kick the habit – according to a recent study. Because the devices allow you to control the strength of nicotine,…
The Harvey L. Neiman Health Policy Institute Launches Cancer Equity Compass
The Harvey L. Neiman Health Policy Institute announces the public launch of a new online tool that reveals the overlap between cancer disparities and social determinants of health (SDOH) using advanced heat maps of U.S. counties. The Cancer Equity Compass can identify high-opportunity targets for policies and programs to achieve equitable health outcomes in underserved populations.
UC Davis total-body advanced PET scanner EXPLORER can visualize dual blood supply in lung cancer
New study shows UC Davis total-body advanced PET scanner EXPLORER can visualize dual blood supply in lungs and effectively evaluate lung cancer and track treatment progress.
New Study Finds Most Eligible U.S. Adults not Getting Screened for Lung Cancer
A new study led by American Cancer Society researchers shows less than one-in-five eligible individuals in the United States were up-to-date with recommended lung cancer screening. The screening uptake was much lower in persons without health insurance or usual source of care and in Southern states with the highest lung cancer burden.
Dr. Estelamari Rodriguez Honored as GRACE Patient Educator of the Year
In recognition of her work breaking down language barriers around the world by creating Spanish-language educational content about lung cancer for patients and caregivers, Sylvester Comprehensive Cancer Center’s Dr. Estelamari Rodriguez has been honored as GRACE Patient Educator of the Year.
New Pathways for Treating Never-Smoker Lung Cancer Revealed
Korean joint research team have elucidated the overexpression of estrogen signaling pathways in specific Korean never-smoking lung cancer cases using multi-omics analysis and proposed the anti-cancer drug saracatinib as a targeted therapeutic agent.
Stress from living in violent neighborhoods tied to aggressive lung cancer in Black men
Exposure to increased neighborhood violence has the power to change the glucocorticoid receptor (GR) for the stress hormone, cortisol, which may influence the aggressiveness of lung cancer, according to data presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Study: Access to Targeted Lung Cancer Drug Is Cost-Prohibitive Globally
A new study that examined the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer, could help guide drug-pricing strategies to reduce financial burdens and increase the number of patients who benefit from treatment.
Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)
Background: KRAS mutant NSCLC remains a therapeutic challenge. Although KRAS G12C inhibitors are now approved for cases harboring that specific mutation, their efficacy is modest and the G12C variant accounts for only 40% of KRAS mutations in NSCLC. To date,…
A meta-analysis of models for predicting the incidence of brain metastasis in patients with lung cancer
Background: Brain metastasis (BM) represents a significant clinical challenge in the management of lung cancer, impacting patient prognosis and treatment decisions. While various predictive models have been developed to assess the risk of BM development, their performance and applicability remain under…
Mount Sinai Experts to Present New Research on Long COVID, Lung Cancer, Asthma, Sleep Apnea, and More at ATS 2024 International Conference
Available for interview on breaking news, trending topics in respiratory medicine
EX-CIGARETTE SMOKERS WHO VAPE MAY BE AT HIGHER RISK FOR LUNG CANCER
Former cigarette smokers who use e-cigarettes or vaping devices may be at higher risk for lung cancer than those who don’t vape, according to research published at the ATS 2024 International Conference.
New imaging software improves lung diagnosis for 30% of patients who can’t tolerate contrast dye; has added diagnostic benefits for all patients
For up to 30% of patients who are allergic to medical contrast dye or have a dye restriction because of other health conditions, they might find that it takes longer to get a diagnosis when it comes to life-threatening lung issues such as pulmonary embolism.
Tip Sheet: Funding awarded to two ovarian cancer research projects, progress towards liquid biopsies for lung cancer — and cannabis and alcohol use in patients
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Study: Hillocks challenge our understanding of lung biology
A research team from Tufts University School of Medicine and Massachusetts General Hospital is now reporting evidence that hillocks and their stem cells are physiologically distinct from other cells within the lung and consist of a stratified outer layer of scale-like squamous cells that protect an underlying layer of rapidly expanding basal stem cells that are capable of restoring airway tissue after injury.
Living with Stage 3 lung cancer in your 80s and 90s
Mickey Allen was 89 years old when she was diagnosed with Stage 3B lung cancer. How did her age impact her treatment options? University of Chicago Medicine oncologists explain what factors they consider when creating treatment plans for patients in their 80s and 90s.
New study confirms community pharmacies can help people quit smoking
New study by UC Davis researchers shows how pharmacies may provide crucial access to tobacco cessation tools that help people successfully quit smoking.
Moffitt Researchers Discover New Therapeutic Target for Non-Small Cell Lung Cancer
A new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies. Their study centers on a molecule called Jagged2, which plays a primary role in fueling the aggressiveness and immune evasion capacity of lung cancer.
University of Maryland Greenebaum Comprehensive Cancer Center and AstraZeneca Partner to Enhance Community-Based Lung Cancer Screening and Detection for Marylanders at High Risk
With only a small percentage of Marylanders at high risk for lung cancer getting the recommended annual screening, the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) today launched a new statewide effort to increase annual screenings.
Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.
Mount Sinai Study Calls for Major Changes in the Way People With Comorbidities Are Selected by Physicians for Lung Cancer Screening
A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients on whether to proceed with lung cancer screening is fraught with confusion and lack of evidence-based information, and may actually be undermining the purpose for which it was created, Mount Sinai researchers say.
MD Anderson Research Highlights for March 20, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
A self-driving needle steers through living lung tissue
The lungs are one of the most difficult organs for physicians to navigate with a conventional bronchoscope. To overcome these limitations, a team of NIH-funded researchers built a compact robotic system that can autonomously steer a flexible needle around these anatomical obstacles within the lungs of live animals.
Study unravels the earliest cellular genesis of lung adenocarcinoma
Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings, published today in Nature, open the door for development of new strategies to detect or intercept the disease in its earliest stages.
Biomarker-directed combination effective in immunotherapy-resistant lung cancer
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.
Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).
Exposure to Even Moderate Levels of Radon Linked to Increased Risk of Stroke
Radon is the second leading cause of lung cancer. Now a new study has found exposure to this invisible, odorless gas is also linked to an increased risk of stroke.
Breakthrough Research Identifies Predictors of Venous Thromboembolism after Pulmonary Resection for Lung Cancer
In patients who undergo pulmonary resection for lung cancer, a major potential postoperative complication is venous thromboembolism (VTE)—a condition that develops when a blood clot forms in a vein—which can lead to part of the clot breaking off and lodging in the lung, resulting in a pulmonary embolism (PE).
Pathologic Scoring Shows Promise for Assessing Lung Tumor Therapy Response
A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.
American Cancer Society Updates Lung Cancer Screening Guideline: Nearly Five Million U.S. Adults who Smoke and Formerly Smoked Now Recommended for Testing
The American Cancer Society releasesan update of its lung cancer screening guideline to help reduce the number of people dying from the disease due to smoking history.
New Study Shows Adults Treated for Non-Small Cell Lung Cancer Vulnerable to Hazards of Wildfires
New research by scientists at the American Cancer Society and the University of California, San Francisco, shows individuals in the United States undergoing radiotherapy for non-small cell lung cancer who are exposed to wildfires near the treating facility have worse overall survival than unexposed individuals.
Antibody-drug conjugate helps patients with metastatic non-small cell lung cancer live longer, delaying disease progression
Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.
Common chemotherapy drugs don’t work like doctors thought, with big implications for drug discovery
A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.
Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.
MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer
MEDSIR, a company specializing in the strategic design of independent clinical research, today presented the results of three new studies at the European Society for Medical Oncology (ESMO 2023).
ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
Perioperative immunotherapy plus neoadjuvant chemotherapy significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC) compared to chemotherapy alone. Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society of Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
MD Anderson Research Highlights: ESMO 2023 Special Edition
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
Cancer researchers awarded $4.6 million to advance liquid biopsy test for early lung cancer detection
A team of investigators from the UCLA Jonsson Comprehensive Cancer Center and the UCLA School of Dentistry received a five-year $4.6 million grant from the National Cancer Institute to develop and improve liquid biopsy technologies for the early detection of lung cancer — the leading cause of cancer death in both men and women in the U.S.
Should a more individualized model replace the current method for determining which people should be screened for lung cancer?
A new study found that an alternative model to identify patients with lung cancer eligible for screening was more accurate than the currently used method based on the United States Preventive Services Task Force (USPSTF) criteria.
Dr. Tanya Stoyanova receives Department of Defense award to find new lung cancer treatments
Dr. Tanya Stoyanova, associate professor of molecular and medical pharmacology and urology at the David Geffen School of Medicine at UCLA, was awarded a $350,000 Idea Development Award from the Department of Defense.
Scientists Successfully Maneuver Robot Through Living Lung Tissue
Ron Alterovitz, PhD, in the UNC Computer Science Department, and Jason Akulian, MD MPH, in the UNC School of Medicine, have shown that their steerable lung robot can autonomously maneuver the intricacies of the lung, while avoiding important lung structures.
Combination immunotherapy treatment effective before lung cancer surgery
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.
Trial: Combination Immunotherapy Prior To Lung Cancer Surgery Appears Promising
Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy. The results were published online Sept. 14 in Cancer Discovery, a journal of the American Association for Cancer Research.
$50 million gift to expand health sciences research at Virginia Tech
The Richmond, Virginia-based Red Gates Foundation recently committed $50 million to the Fralin Biomedical Research Institute at VTC to accelerate health sciences research at Virginia Tech. The gift is among the largest ever made to the university.
Intensity-modulated radiation therapy provides long-term benefits to patients with locally advanced lung cancer
Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the heart and lungs, according to researchers at The University of Texas MD Anderson Cancer Center.
AI more accurately identifies patients with advanced lung cancer that respond to immunotherapy and helps doctors select treatments
Treatment planning for lung cancer can often be complex due to variations in assessing immune biomarkers. In a new study, Yale Cancer Center researchers at Yale School of Medicine used artificial intelligence (AI) tools and digital pathology to improve the accuracy of this process.